Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Decitabine vs Azacitidine in Low/Int-1 Risk MDS
NCT01720225Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2012
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2012; status: completed.
02
Drugs
decitabineazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01720225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01720225.